Clinical Characterization of Symptomatic Populations - Trial NCT03319212
Access comprehensive clinical trial information for NCT03319212 through Pure Global AI's free database. This phase not specified trial is sponsored by Johnson & Johnson Vision Care, Inc. and is currently Completed. The study focuses on Ametropia. Target enrollment is 105 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Johnson & Johnson Vision Care, Inc.
Timeline & Enrollment
N/A
Sep 29, 2017
Aug 15, 2018
Primary Outcome
Meibomian Gland Imaging,Meibomian Gland Expressibility,Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings,Lid Wiper Epitheliopathy,Conjunctival Folds
Summary
This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of
 symptomatic and asymptomatic subject populations. Subjects will be assigned to a single study
 lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear
 for 1 week.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03319212
Device Trial